150989-61-0

Basic information

• Product Name: 1H-Azepine-1-carboxylic acid, 4-aminohexahydro-3-hydroxy-, phenylmethyl ester
• CAS NO: 150989-61-0
• Molecular Formula: C14H20N2O3
• Molecular Weight: 264.324
• Mol File: 150989-61-0.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 1H-Azepine-1-carboxylic acid, 4-aminohexahydro-3-hydroxy-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Azepine-1-carboxylic acid, 4-aminohexahydro-3-hydroxy-, phenylmethyl ester(150989-61-0)
• EPA Substance Registry System: 1H-Azepine-1-carboxylic acid, 4-aminohexahydro-3-hydroxy-, phenylmethyl ester(150989-61-0)

Safety Data

• Hazardous Substances Data: 150989-61-0(Hazardous Substances Data)

Usage

Molecular weight

279.36 g/mol

Chemical structure

1H-Azepine-1-carboxylic acid, 4-aminohexahydro-3-hydroxy-, phenylmethyl ester

Functional class

GABA agonist

Therapeutic uses

Insomnia, anxiety disorders, and alcohol withdrawal symptoms

Side effects

Drowsiness, dizziness, and impaired coordination

Status

Discontinued in some countries due to safety concerns.

Upstream product

• 150989-59-6 8-oxo-3-azabicyclo[5.1.0]octane-3-carboxylic acid benzyl ester 
• 281219-33-8 4-azido-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 501-53-1 benzyl chloroformate 
• 5041-33-8 N-(Benzyloxycarbonyl)allylamine 
• 281219-32-7 allylpent-4-enylcarbamic acid benzyl ester 
• 150989-62-1 2,3,4,7-tetrahydro-azepine-1-carboxylic acid benzyl ester 
• 281221-20-3 4-tert-butoxycarbonylamino-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 150989-58-5 2,5,6,7-Tetrahydro-1H-azepine 
• 3349-62-0 cyclohex-2-enone oxime 
• 930-68-7 cyclohexenone 
• 2228-79-7 1,5,6,7-Tetrahydro-2H-azepin-2-one 

Downstream Products

• 281219-34-9 4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-carboxylic acid benzyl ester 
• 369593-24-8 {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenylethyl}carbamic acid tert-butyl ester 
• 369593-26-0 Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide 
• 281217-45-6 SB 357114 
• 281219-45-2 4(R,S)-((S)-1-{3(R,S)-hydroxy-1-[2-(3-pyridin-2-ylphenyl)ethanoyl]azepan-4-ylcarbamoyl}-3-methylbutyl)carbamic acid tert-butyl ester 
• 281219-31-6 ((S)-1-{1-[4(R,S)-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-3-(R,S)-hydroxyazepan-1-yl]-methanoyl}-3-methylbutyl)carbamic acid benzyl ester 
• 281214-55-9 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{(R)-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-amide 
• 281217-40-1 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{(S)-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-amide 
• 281219-64-5 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-3-methyl-butyl)-amide 
• 678982-30-4 benzyl 3-hydroxy-4-[(N-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucine)amino]azepane-1-carboxylate 
• 556063-40-2 [1-(3-hydroxy-azepan-4-ylcarbamoyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 281221-45-2 4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 1247884-57-6 benzyl 3-hydroxy-4-picolinamidoazepane-1-carboxylate 

Relevant articles and documents

M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Q, X, Y, Z, R1, R7 and n are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modul

Methods of treatment

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin L in the treatment of diseases in which cathepsin L is implicated, especially treatment or prevention of rheumatoid arthritis; treatment or prevention of cancer metastasis; treatment or prevention of diseases requiring inhibition of tissue destruction by macrophage, particularly lung macrophage, such as asthma, chronic obstructive pulmonary disease (COPD), and emphysema; treatment or prevention of diseases requiring, for therapy, inhibition of positive selection of CD4+ T-cells by cortical thymic epithelial cells.

Protease inhibitors

The present invention provides C3-C6 1-amino-1-acyl cycloalkane-substituted 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K,